Experimental Weight Loss Data
Eli Lilly reports experimental weight-loss drug trials show up to 25% reduction.
Anonymous
Eli Lilly reported that an experimental combination of eloralintide and tirzepatide produced up to 23.3% average weight loss over 48 weeks in a mid-stage trial of people with obesity and Type 2 diabetes, compared with 14.8% for high-dose tirzepatide alone; Lilly said it planned Phase 3 trials by year-end. Separately, studies of experimental retatrutide found weight loss of about 18.8% among participants with Type 2 diabetes and up to 25% among those without diabetes, alongside improvements in diabetes control and reported benefits for knee pain and sleep apnea. Lilly also said an indirect comparison found its oral drug Foundayo 17.2 mg produced 1.5% greater weight loss and a 0.3% greater A1C reduction than oral semaglutide 25 mg in adults with Type 2 diabetes over 52 weeks, with Foundayo participants seeing 9.2% weight loss and a 2.2% A1C reduction. The Foundayo analysis used separate Lilly and Novo Nordisk trials, not a head-to-head study, and Novo argued it concerned people with diabetes rather than those seeking obesity treatment. The findings were reported amid growing competition in oral diabetes and obesity treatments.
Key Points
1
In the Phase 2 combination trial, eloralintide alone produced up to 12.3% average weight loss, compared with 14.8% for tirzepatide alone and up to 23.3% for the combination. Lilly said the combination pairs amylin-targeting eloralintide with a low dose of tirzepatide, which targets GLP-1 and GIP.
2
In the retatrutide study of people with Type 2 diabetes, about one-third of participants on the highest dose lost at least 25% of their body weight, versus 3% on placebo, over 1.5 years. Also, 63% of those on the highest dose both reduced their A1C below 6.5% and lost at least 10% of their weight.
3
Retatrutide targets GLP-1, GIP and glucagon. In the study of people without diabetes, 3.9% of placebo recipients lost at least 25% of their starting body weight, compared with those on the highest retatrutide dose who lost about 25% on average.
4
For the Foundayo comparison, Lilly drew on its ACHIEVE-3 trial and Novo Nordisk’s PIONEER PLUS study, adjusting results for participants’ age, gender, starting weight and baseline A1C. The analysis was presented at the EASD annual meeting in Milan.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
27
Reach
48
A
AnonymousAuthor
